ArticleNature cancer2022
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.
Ido Yofe et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
55 papers cite it
this papertrialcites it